LT3001 Drug clinical trials
LT3001 Drug is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Phase 2. The lead sponsor is Shanghai Pharmaceuticals Holding Co., Ltd. The most-studied condition is Acute Ischemic Stroke.
Patient leaflets for LT3001 Drug
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of LT3001 Drug
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
|
Phase 2 | Recruiting | Shanghai Pharmaceuticals Holding Co., Ltd | China |
|
A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
NCT07754825 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
|
Phase 2 | Not yet open | Shanghai Pharmaceuticals Holding Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with LT3001 Drug
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Shanghai Pharmaceuticals Holding Co., Ltd | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about LT3001 Drug trials
How many clinical trials are testing LT3001 Drug?
2 current trials in our China register name LT3001 Drug as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are LT3001 Drug trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors LT3001 Drug clinical trials?
The lead sponsor is Shanghai Pharmaceuticals Holding Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how LT3001 Drug works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how LT3001 Drug works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists LT3001 Drug (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.